Werewolf Therapeutics (NASDAQ:HOWL) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Werewolf Therapeutics (NASDAQ:HOWL) from a sell rating to a hold rating in a report released on Tuesday morning.

A number of other brokerages have also issued reports on HOWL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, January 21st. Citizens Jmp lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. HC Wainwright decreased their target price on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, December 19th. Citigroup lowered Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Finally, Wedbush lowered Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research report on Friday, December 19th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Price Performance

Shares of NASDAQ:HOWL opened at $1.00 on Tuesday. Werewolf Therapeutics has a 1 year low of $0.53 and a 1 year high of $2.38. The firm has a market capitalization of $48.60 million, a price-to-earnings ratio of -0.74 and a beta of 0.54. The business’s 50 day moving average price is $0.74 and its 200-day moving average price is $1.00.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Friday, March 27th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.14. On average, sell-side analysts expect that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Luke Evnin sold 58,980 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $0.57, for a total value of $33,618.60. Following the completion of the transaction, the director directly owned 2,309,869 shares of the company’s stock, valued at approximately $1,316,625.33. This represents a 2.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 241,383 shares of company stock valued at $136,263. 23.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics in the 2nd quarter valued at $48,000. Regal Investment Advisors LLC raised its stake in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after purchasing an additional 25,389 shares during the last quarter. Vontobel Holding Ltd. raised its stake in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after purchasing an additional 24,003 shares during the last quarter. AQR Capital Management LLC acquired a new position in Werewolf Therapeutics in the 1st quarter valued at $79,000. Finally, Susquehanna International Group LLP raised its stake in Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares during the last quarter. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.